BREMEN, Germany--(BUSINESS WIRE)--Sep. 15, 2009--
Prior to the 61st Annual
Meeting of the German Society for Hygiene and Microbiology on
September 20-23, 2009 in Goettingen, Bruker Daltonics announces a new
framework agreement with the Limbach laboratory network, concerning
microbial identification based on MALDI-TOF mass spectrometry. According
to the agreement, Bruker Daltonics will be the exclusive provider of
MALDI-TOF based microbial identification solutions for the Limbach
network of more than 30 European clinical laboratories.
Since being introduced at the Labor
Limbach headquarters in Heidelberg in 2007, the MALDI
Biotyper has been established in a number of other
laboratories in the Limbach association. The MALDI Biotyper
is currently in use in Limbach clinical microbiology centers in Germany
in Heidelberg, Koblenz, Hamburg, Karlsruhe, Singen, Magdeburg and
Nordhorn. After the signing of the new framework agreement, Bruker has
received additional orders for MALDI Biotyper systems from
the Limbach laboratories in Ravensburg and in Freiburg, and an
additional system was ordered for Limbach site in Heidelberg. The
Limbach laboratory network intends to introduce this new molecular
technology broadly as a very fast routine method for microbial
identification in additional Limbach laboratories in Germany. Moreover,
Bruker and Labor Limbach intend to jointly introduce the MALDI
Biotyper in Poland via Limbach´s laboratories in Warsaw and
Gdansk.
Dr. Anne-Marie Fahr, Head of Microbiology at Labor Limbach, commented:
“In contrast to previous introductions of other technologies, in the
case of the MALDI Biotyper we have seen a very wide
acceptance of this new approach nearly throughout our entire network.
Bruker is the leading supplier of MALDI-TOF mass spectrometry with a
global support and service network, and is thus the reliable long-term
partner that we were looking for in the Limbach association.”
Dr. Wolfgang Pusch, Vice President for Clinical Research Solutions & IVD
at Bruker Daltonics, added: “This exclusive framework agreement is a
major step ahead into a new era of fast molecular identification in
clinical microbiology. The last two years have shown the fundamental
advantages of our MALDI Biotyper approach for microbial
identification, i.e. higher specificity, faster time-to-result and lower
consumables costs. Moreover, the MALDI Biotyper has proven
to be robust and easy to use in demanding environments. We are very
pleased that our MALDI Biotyper fulfils the high
expectations of leading clinical laboratories like the Labor Limbach
association, and we look forward to presenting the IVD-CE marked MALDI
Biotyper at the upcoming 61st DGHM Annual Meeting.”
About the Bruker MALDI Biotyper
Bruker’s dedicated MALDI
Biotyper solution enables molecular identification,
taxonomical classification or dereplication of microorganisms like
bacteria, yeasts and fungi. Classification and identification of
microorganisms is achieved reliably and quickly using proteomic
fingerprinting by high-throughput MALDI-TOF mass spectrometry.
Applications include clinical routine microbial identification,
environmental and pharmaceutical analysis, taxonomical research, food
and consumer product processing and quality control, as well as marine
microbiology. Bruker’s robust MALDI Biotyper method
requires minimal sample preparation efforts and offers low consumables
cost per sample. The MALDI Biotyper is available in a
research-use-only version, as well as in an IVD-CE version according to
EU directive EC/98/79 in certain European countries. For more
information, please visit www.bdal.com/maldibiotyper.
ABOUT BRUKER DALTONICS
For more information about Bruker Daltonics and Bruker Corporation
(NASDAQ: BRKR), please visit www.bdal.com
and www.bruker.com.
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and uncertainties.
The factors that could cause actual future results to differ materially
from current expectations include, but are not limited to, risks and
uncertainties relating to adverse changes in conditions in the global
economy and volatility in the capital markets, the integration of
businesses we have acquired or may acquire in the future, changing
technologies, product development and market acceptance of our products,
the cost and pricing of our products, manufacturing, competition,
dependence on collaborative partners and key suppliers, capital spending
and government funding policies, changes in governmental regulations,
intellectual property rights, litigation, and exposure to foreign
currency fluctuations. These and other factors are identified and
described in more detail in our filings with the SEC, including, without
limitation, our annual report on Form 10-K for the year ended December
31, 2008, our most recent quarterly reports on Form 10-Q and our current
reports on Form 8-K. We disclaim any intent or obligation to update
these forward-looking statements other than as required by law.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6048603&lang=en
Source: Bruker Daltonics
MALDI Biotyper Marketing, Bruker Daltonics
Karin Hoffmann,
+49-421-2205-2041
kho@bdal.de